All In Biotech

Drug Trial Radar · NCT03121586

Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia

A 52-Week, Open-Label, Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia

Last checked: Nov 20, 2026Latest source record: Aug 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

995

Actual

Start

Jan 2017

Primary completion

Apr 30, 2024

Study completion May 30, 2024

Sponsor

Lead sponsor
ACADIA Pharmaceuticals Inc.Industry
Sponsor type
Industry
First posted
Apr 20, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the long-term safety and tolerability of pimavanserin after 52 weeks of adjunctive treatment in subjects with schizophrenia

Conditions

  • Schizophrenia

Interventions

  • PimavanserinDrug

    Pimavanserin 10 mg, tablet, taken as one 10 mg tablets, once daily by mouth, OR Pimavanserin 20 mg, tablet, taken as two 10 mg tablets, once daily by mouth, OR Pimavanserin 34 mg, tablet, taken as two 17 mg tablets, once daily by mouth

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment Emergent Adverse EventsTime frame: Treatment period (52 weeks) and follow-up period (30 days): planned total of 56 weeks. Since the study was prematurely terminated, the reporting period was shortened; AEs were assessed to the end of treatment, at a mean duration of 319 days (or 46 weeks).

Locations

161 sites in 14 countries. Site status is shown where the registry gives one.

  • 171-Alea Research Institute

    Phoenix, Arizona

  • 156-Woodland International Research Group, LLC

    Little Rock, Arkansas

  • 111-Woodland Research Northwest, LLC

    Rogers, Arkansas

  • 167-CITrials - Bellflower

    Bellflower, California

  • 105-ProScience Research Group

    Culver City, California

  • 123-Synergy San Diego

    Lemon Grove, California

  • 164-Artemis Institute for Clinical Research

    San Diego, California

  • 165-CITrials

    Santa Ana, California

  • 108-Collaborative Nueroscience Network, LLC

    Torrance, California

  • 125-Galiz Research

    Hialeah, Florida

  • 137-Innovative Clinical Research, Inc.

    Lauderhill, Florida

  • 146-Premier Clinical Research Institute, Inc.

    Miami, Florida

  • 162-Synexus Clinical Research, Inc.

    Atlanta, Georgia

  • 168-Atlanta Center for Medical Research

    Atlanta, Georgia

  • 102-Northwest Behavioral Research Center

    Marietta, Georgia

  • 114-Northwestern University

    Chicago, Illinois

  • 101-American Medical Research

    Chicago, Illinois

  • 130-Alexian Brothers Center for Psychiatric Research

    Hoffman Estates, Illinois

  • 118-Lake Charles Clinical Trials

    Lake Charles, Louisiana

  • 124-Altea Research Institute

    Las Vegas, Nevada

  • 141-Hassman Research Institute

    Berlin, New Jersey

  • 153-Albuquerque Neuroscience Inc.

    Albuquerque, New Mexico

  • 104-Neurobehavioral Research, Inc.

    Cedarhurst, New York

  • 140-Synexus Clinical Research, Inc - 140

    Jamaica, New York

  • 128-Finger Lakes Clinical Research

    Rochester, New York

  • 106-New Hope Clinical Research

    Charlotte, North Carolina

  • 145-Carolina Behavioral Care

    Durham, North Carolina

  • 110-Cutting Edge Research Group

    Oklahoma City, Oklahoma

  • 170-Suburban Research Associates

    Downingtown, Pennsylvania

  • 127-University Hills Clinical Research

    Irving, Texas

  • 103-Pillar Clinical Research, LLC

    Richardson, Texas

  • 115-Psychiatric and Behavioral Solutions LLC

    Salt Lake City, Utah

  • 610-Clinica Privada Banfield S.A.

    Buenos Aires, Argentina

  • 625-NOVAIN Neurociencias Group

    Buenos Aires, Argentina

  • 603-Fundación para el Estudio y Tratamiento de las Enfermedades Mentales - FETEM

    Ciudad Autonoma Buenos Aires, Argentina

  • 601-CENydET- Centro Neurobiologico y de Estres Traumatico-Biopsychomedical Research Group SRL

    Ciudad Autonoma de Buenos Aire, Argentina

  • 602-FunDamoS

    Ciudad Autonoma de Buenos Aire, Argentina

  • 622-Instituto Medico Damic Srl

    Córdoba, Argentina

  • 624-Centro Especializado en Neurociencias CEN

    Córdoba, Argentina

  • 626-Sanatorio Prof. Leon S. Morra S.A.

    Córdoba, Argentina

Showing 40 of 161 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.